Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (ATHA) is a clinical-stage biopharmaceutical company pioneering novel therapeutics targeting neurodegenerative diseases through modulation of the HGF system. This page aggregates official press releases, clinical trial updates, and strategic developments related to their pipeline of small molecule candidates.
Investors and researchers will find timely updates on regulatory milestones, partnership announcements, and scientific presentations. Key content includes progress reports on lead candidate fosgonimeton (ATH-1017) for Alzheimer's disease, updates on oral therapies ATH-1020 and ATH-1105, and analyses of biomarker-driven trial outcomes.
All materials are sourced directly from the company's investor relations communications and verified industry publications. Bookmark this page for streamlined access to Athira Pharma's latest advancements in neuroprotection research and therapeutic development.
Athira Pharma has completed the first cohort in its Phase 1 clinical trial for ATH-1105, a potential treatment for ALS. This first-in-human, dose-escalation study aims to assess the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. The trial is expected to conclude by the end of 2024, with a Phase 2 study in ALS patients slated for 2025. Preclinical data indicates that ATH-1105 can improve motor function, preserve nerve health, and extend survival in ALS models. The Phase 1 trial will involve up to 80 healthy participants and will evaluate single and multiple ascending doses of the drug.
Athira Pharma (NASDAQ: ATHA), a late-stage clinical biopharmaceutical company, announced its participation in two investor conferences in June 2024. The company will present at the Jefferies Healthcare Conference on June 5 and the Goldman Sachs 45th Annual Healthcare Conference on June 12. These events will feature fireside chats where Athira’s management will discuss the company’s robust pipeline focused on neurodegenerative diseases. They will also highlight the progress of the LIFT-AD Phase 2/3 trial in Alzheimer’s Disease, with topline data expected in the second half of 2024. The fireside chats will be webcast live on Athira's Investor Relations website, with replays available for 30 days post-event.
Athira Pharma (NASDAQ: ATHA) announced a proposed settlement for stockholder derivative actions. The settlement, preliminarily approved by the U.S. District Court for the Western District of Washington, involves adopting corporate governance reforms and paying legal fees and service awards to lead plaintiffs. A final approval hearing is scheduled for July 18, 2024. Relevant documents have been posted on Athira's Investor Relations website.
Athira Pharma (NASDAQ: ATHA) released its Q1 2024 financial results and highlighted pipeline and business updates. The company is anticipating topline data from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for Alzheimer's disease in H2 2024. They've also filed an IND application for ATH-1105 for ALS treatment and plan a first-in-human study in Q2 2024. Financially, Athira reported a net loss of $26.3 million, or $0.69 per share, compared to $27.8 million, or $0.73 per share, in Q1 2023. Cash reserves stand at $122.1 million, down from $147.4 million in December 2023. R&D expenses were $21.2 million, while G&A expenses dropped to $6.5 million. The company remains focused on advancing its small molecule drug candidates targeting the HGF system to treat neurodegenerative diseases.
Summary: Athira Pharma, Inc. (NASDAQ: ATHA) will be participating in the Sidoti May 2024 Virtual Investor Conference and The Citizens JMP Life Sciences Conference in May. The Company management will present at these conferences to discuss their focus on developing small molecules to restore neuronal health and slow neurodegeneration. Live webcasts and archived replays will be available on the Athira website.
FAQ
What is the current stock price of Athira Pharma (ATHA)?
What is the market cap of Athira Pharma (ATHA)?
